ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessing the Power of the Repeatome $50 Million Series A Financing Led by GV and ARCH Venture Partners with Participation from Partners Innovation Fund Initial Targets Identified and Multiple Programs Advancing as ROME Opens Uncharted Genomic Regions to Drug Discovery CAMBRIDGE, Mass., April 27, 2020-- ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, launched today with $50 million in Series A funding from GV, ARCH Venture Partners and Partners Innovation Fund.